ZEUS-CVOT
Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
- Stage
- followup
- Medicine
- Ziltivekimab
- Population
- ASCVD
- Phase
- III
- First Patient In
- 8 October 2021
- Last Patient In
- 10 April 2024
- Last Patient Last Visit
- 26 June 2026
National Lead
prof. dr. J.H. Cornel
Cardioloog
Office Contact
